Clinical trial · Interventional
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
NCT00964873CI-TRIAL-00015640completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| ALL | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Blast-phase Chronic Myelogenous Leukemia | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
| CML | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STA-9090 (ganetespib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1 Part 1
- interventionNames
- Drug: STA-9090 (ganetespib)
Primary outcomes (1)
- measure
- To assess efficacy in subjects with AML, ALL and blast-phase CML based on standard response criteria
- timeFrame
- every 8 weeks
Secondary outcomes (1)
- measure
- To characterize the safety and tolerability of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML
- timeFrame
- ongoing
- description
- as per adverse event and serious adverse event reporting
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with a pathologic confirmation of the diagnosis of AML, ALL, or blast-phase CML * ECOG Performance Status 0-2 * Adequate organ function as defined in the protocol. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Hyperleukocytosis * Acute Promyelocytic Leukemia (FAB-M3) subtype * Uncontrolled Disseminated Intravascular Coagulation (DIC) * Active central nervous system leukemia * Concomitant radiation therapy, chemotherapy, or immunotherapy * Women who are pregnant or lactating * Neuropathy ≥ grade 2 (NCI CTCAE) at time of enrollment * Chemotherapy (with the exception of hydroxyurea) or radiotherapy within two weeks or within six times the agent's half life * Require ongoing therapy with either G- or GM-CSF, or long-acting versions of these molecules * Use of any investigational agents within two weeks or within six times the agent's half life --Treatment with chronic immunosuppressants * Other medical/psychiatric condition that may increase the risk associated with study participation as defined by the protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.